XNASMNPR
Market cap154mUSD
Jan 10, Last price
25.35USD
1D
3.64%
1Q
360.91%
IPO
-81.22%
Name
Monopar Therapeutics Inc
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
6.85%
Rev. gr., 5y
%
Revenues
0k
Net income
-8m
L-19.94%
CFO
-8m
L+8.71%
Earnings
Mar 26, 2025
Profile
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to potentially treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was incorporated in 2014 and is headquartered in Wilmette, Illinois.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | (3,218,980) | 10,537 | |||||||
Unusual Expense (Income) | |||||||||
NOPBT | 3,218,980 | (10,537) | |||||||
NOPBT Margin | |||||||||
Operating Taxes | (21) | ||||||||
Tax Rate | |||||||||
NOPAT | 3,218,980 | (10,516) | |||||||
Net income | (8,402) -19.94% | (10,494) 15.59% | |||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | 2,074 | 109 | |||||||
BB yield | -42.02% | -0.36% | |||||||
| Debt | |||||||||
Debt current | 49 | ||||||||
Long-term debt | 17 | ||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | (7,266) | (13,054) | |||||||
| Cash flow | |||||||||
Cash from operating activities | (7,858) | (7,229) | |||||||
CAPEX | |||||||||
Cash from investing activities | 4,928 | (4,919) | |||||||
Cash from financing activities | 2,027 | 33 | |||||||
FCF | 3,219,028 | (10,577) | |||||||
| Balance | |||||||||
Cash | 7,266 | 13,120 | |||||||
Long term investments | |||||||||
Excess cash | 7,266 | 13,120 | |||||||
Stockholders' equity | (60,205) | (51,782) | |||||||
Invested Capital | 65,793 | 61,929 | |||||||
ROIC | 5,040.60% | ||||||||
ROCE | 57,607.63% | ||||||||
| EV | |||||||||
Common stock shares outstanding | 14,511 | 12,718 | |||||||
Price | 0.34 -85.65% | 2.37 -26.17% | |||||||
Market cap | 4,937 -83.62% | 30,142 -24.71% | |||||||
EV | (2,329) | 17,088 | |||||||
EBITDA | 3,218,980 | (10,537) | |||||||
EV/EBITDA | |||||||||
Interest | 21 | ||||||||
Interest/NOPBT | |||||||||